Heranova Lifesciences

Happy holidays from Heranova! Click here for a special holiday message from Co-Founder and Chairwoman, Penny Wan bit.ly/3ZQms2w

Data from Cleveland Clinic underscores the critical link between gynecologic and gastrointestinal (GI) symptoms in women with #endometriosis. The retrospective review of over 6,700 patient records revealed that women with endometriosis experience significantly more GI symptoms such as nausea, bloating, and gastroparesis compared to women without the condition. They also utilize healthcare services at much higher rates, including emergency visits and abdominal surgeries. The findings emphasize the need for integrated care and earlier screening for gynecologic conditions in women with persistent GI issues. Early intervention could reduce diagnostic delays and improve patient outcomes. Read more: https://bit.ly/401rOtg At Heranova, we are committed to advancing diagnostic solutions for women’s health. Our non-invasive blood test, HerResolve, aims to address diagnostic gaps by providing earlier and more accurate detection of endometriosis, helping improve lives through timely care. Visit Heranova.com to learn more. #GIHealth #Heranova #HerResolve #EndometriosisAwareness 

A study published in the Cureus Journal of Medical Science compares key treatment strategies for managing #endometriosis-related pain, emphasizing the importance of personalized care tailored to symptom severity, reproductive goals, and patient preferences. Heranova is advancing innovative women's health solutions like HerResolve, our non-invasive, blood-based diagnostic test for endometriosis. We believe in empowering women with earlier, accurate diagnoses for better treatment outcomes. Visit Heranova.com to learn more.  #EndometriosisCare #PainManagement #WomensHealth #Heranova #HerResolve

Data presented at the 2024 ASCO Quality Care Symposium revealed a significant rise in molecular biomarker testing rates for advanced and recurrent endometrial cancer. Between 2013 and 2021, testing increased from 53% to 89%, driven by better adoption of clinical guidelines. Biomarkers like MMR/MSI saw the largest increase, reflecting advances in personalized treatment strategies. Read more here: https://bit.ly/3ZB9zcr At Heranova, we are committed to advancing diagnostic precision using biomarker technology. With HerResolve, our non-invasive, blood-based diagnostic test, we aim to close the gap in early detection and personalized care for women’s health conditions like #endometriosis. Visit Heranova.com to learn more. #EndometrialCancer #PrecisionOncology #BiomarkerTesting #Heranova #HerResolve

Building on the momentum from the US launch of our early access program for HerResolve earlier this year, Heranova is delighted to further expand early access internationally in Asia. We would like to sincerely thank The Hong Kong Society for Reproductive Medicine and IVF-Worldwide for the opportunity to share our innovative blood test for the detection of endometriosis at the 2024 Ovarian Club Asia Conference. Please visit Heranova.com to learn more about how we are advancing non-invasive diagnostic solutions and how you can participate in our early access program for HerResolve. #Heranova #HerResolve #EndometrioisDiagnosis #WomensHealth 

Can too much zinc in your diet put you at risk for #endometriosis? A recent study suggests a potential link between higher dietary zinc intake and an increased risk of endometriosis. Researchers analyzed data from over 4,000 women, finding that consuming more than 14 mg/day of zinc was associated with a 60% higher risk compared to those consuming less than 8 mg/day. While zinc plays a crucial role in immune function and tissue repair, excess intake may influence enzymes and pathways linked to endometriosis progression. Read the full study here: https://bit.ly/4g03yND Heranova is transforming endometriosis diagnosis with HerResolve, a non-invasive, blood-based test designed to confirm the presence or absence of endometriosis in symptomatic women. Learn more at Heranova.com. #Heranova #HerResolve #WomensHealth

Heranova is excited to announce the launch of HerResolve™, a groundbreaking non-invasive test for endometriosis, at the 2024 Ovarian Club Asian Conference on December 14-15 at the Hong Kong Convention and Exhibition Centre. With 92% diagnostic accuracy, HerResolve offers a safer, more efficient alternative to traditional methods, addressing a critical need for millions of women. Visit our booth to meet with members of our expert team and learn more about this innovation as well as how to participate in the early access program for HerResolve. Read more here: https://bit.ly/3PeqOfb #Heranova #HerResolve #EndometriosisDiagnosis #WomensHealth 

Living with #endometriosis means enduring years of pain, delayed diagnoses, and inadequate follow-up care. This article from Cosmopolitan UK sheds light on one woman’s experience, from suffering in silence since age 12 to finally securing a diagnosis through private surgery. Her story reflects the broader struggles of many: the average diagnosis still takes 7.5 years, and recent research shows this has worsened post-pandemic. The article also ties in the Netflix film Joy, which not only explores the invention of IVF but highlights the devastating impact of endometriosis on fertility. Jean Purdy’s fight to develop IVF was deeply personal—rooted in her own battle with endometriosis. While systemic barriers remain, there’s hope that advancements in diagnostics and care will make a real difference in the coming years. https://bit.ly/3D2OnVc Heranova is proud to be at the forefront of this change. With HerResolve, we’ve developed a non-invasive, blood-based diagnostic test that provides faster, more accurate endometriosis detection—eliminating the need for invasive surgeries. Visit Heranova.com to learn how HerResolve can empower women with answers and accelerate access to better care. #Heranova #HerResolve #WomensHealth #IVF

New data published in Obstetrics & Gynecology highlights the pivotal role fibrosis plays in #endometriosis by contributing to lesion formation, a stiff microenvironment, and endometriosis-associated pain. Insights into pro-fibrotic pathways, including TGF-β signaling, offer potential for non-hormonal therapies targeting fibrosis. Additionally, the unique link between nerves and fibrosis in endometriotic lesions underscores its role in pain mechanisms and therapeutic innovation. Read the full study here: https://bit.ly/415Fy6X At Heranova, we understand that early detection of endometriosis is critical to addressing pain and improving quality of life. HerResolve, our non-invasive diagnostic test, empowers patients and providers with timely, accurate information, enabling earlier interventions and better management strategies. Together, we’re advancing care for endometriosis. Visit Heranova.com to learn more. #Heranova #HerResolve #WomensHealth #fibrosis

#Endometriosis is a complex condition affecting millions of women worldwide, yet it remains widely misunderstood and under-researched. To empower patients with accurate information, the American Society for Reproductive Medicine - ASRM has developed a comprehensive guide on understanding and managing endometriosis. Access the guide here: https://bit.ly/3Db32xx At Heranova, we’re dedicated to addressing the gaps in endometriosis care through innovation. Our flagship solution, HerResolve, provides a non-invasive, blood-based diagnostic option to help women achieve faster, more accurate diagnoses. Together, we can work towards a future where endometriosis is no longer overlooked. For more information, please visit Heranova.com #Heranova #HerResolve #WomensHealth #ASRM